- Home
- COPL vs TLSI Comparison
COPL vs TLSI Comparison
Compare COPL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COPL
- TLSI
- Stock Information
- Founded
- COPL 2024
- TLSI 2010
- Country
- COPL Hong Kong
- TLSI United States
- Employees
- COPL N/A
- TLSI N/A
- Industry
- COPL
- TLSI Medical Specialities
- Sector
- COPL
- TLSI Health Care
- Exchange
- COPL NYSE
- TLSI Nasdaq
- Market Cap
- COPL 238.0M
- TLSI 204.0M
- IPO Year
- COPL 2025
- TLSI N/A
- Fundamental
- Price
- COPL $10.03
- TLSI $4.89
- Analyst Decision
- COPL
- TLSI Strong Buy
- Analyst Count
- COPL 0
- TLSI 5
- Target Price
- COPL N/A
- TLSI $10.90
- AVG Volume (30 Days)
- COPL 3.7K
- TLSI 153.7K
- Earning Date
- COPL 01-01-0001
- TLSI 08-13-2025
- Dividend Yield
- COPL N/A
- TLSI N/A
- EPS Growth
- COPL N/A
- TLSI N/A
- EPS
- COPL N/A
- TLSI N/A
- Revenue
- COPL N/A
- TLSI $32,141,000.00
- Revenue This Year
- COPL N/A
- TLSI $55.52
- Revenue Next Year
- COPL N/A
- TLSI $54.76
- P/E Ratio
- COPL N/A
- TLSI N/A
- Revenue Growth
- COPL N/A
- TLSI 46.20
- 52 Week Low
- COPL $10.00
- TLSI $3.50
- 52 Week High
- COPL $10.14
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- COPL N/A
- TLSI 42.89
- Support Level
- COPL N/A
- TLSI $4.85
- Resistance Level
- COPL N/A
- TLSI $5.11
- Average True Range (ATR)
- COPL 0.00
- TLSI 0.30
- MACD
- COPL 0.00
- TLSI -0.03
- Stochastic Oscillator
- COPL 0.00
- TLSI 13.45
About COPL COPLEY ACQUISITION CORP
Copley Acquisition Corp is a blank check company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.